Background: Atherosclerosis is characterized by lipid accumulation and chronic inflammation in the arterial wall. Elevated levels of apolipoprotein (apo) B-containing lipoproteins are a risk factor for cardiovascular disease (CVD). By contrast, plasma levels of functional high-density lipoprotein (HDL) and apoA-I are protective against CVD by enhancing reverse cholesterol transport (RCT). Activation of peroxisome proliferator-activated receptor-a (PPARa), a ligand-activated transcription factor, controls lipid metabolism, cellular cholesterol trafficking in macrophages and influences inflammation. Objective: To study whether pharmacological activation of PPARa with a novel highly potent and selective PPARa modulator, pemafibrate, improves lipid metabolism, macrophage cholesterol efflux, inflammation and consequently atherosclerosis development in vitro and in vivo using human apolipoprotein E2 Knock-In (apoE2KI) and human apoA-I transgenic (hapoA-I tg) mice. Approach and results: Pemafibrate treatment decreases apoB secretion in chylomicrons by polarized Caco-2/TC7 intestinal epithelium cells and reduces triglyceride levels in apoE2KI mice. Pemafibrate treatment of hapoA-I tg mice increases plasma HDL cholesterol, apoA-I and stimulates RCT to feces. In primary human macrophages, pemafibrate promotes macrophage cholesterol efflux to HDL and exerts anti-inflammatory activities. Pemafibrate also reduces markers of inflammation and macrophages in the aortic crosses as well as aortic atherosclerotic lesion burden in western diet-fed apoE2KI mice.
Introduction
Atherosclerosis is a pathological process in which lipid deposition in the intima and media of the arterial wall promotes formation of plaques. Atherosclerotic plaques result from the progressive accumulation of cholesterol and diverse lipids in native and oxidized forms, extracellular matrix and inflammatory cells [1, 2] . Atherogenic dyslipidemia, a cardiovascular risk factor for atherosclerosis, is an imbalance between pro-atherogenic apoB-containing lipoproteins (Chylomicrons and VLDL remnants, LDL) and antiatherogenic apoA-I containing HDL. Reduction of atherogenic dyslipidemia is therefore considered as a pharmacological approach to treat CVD [3] .
Fibrates are used in the clinical management of dyslipidemia [4] . They lower triglycerides (TG) and, to differing extents, LDL-C and modestly increase HDL-C [5] . Fibrates activate a transcription factor belonging to the nuclear receptor superfamily, PPARa. PPARa is also activated by various natural ligands, like eicosanoids and fatty acids. Following ligand activation, PPARa heterodimerizes with the retinoid X receptor and binds PPAR response elements (PPRE) localized in the regulatory regions of target genes, thus regulating genes involved in many biological processes, such as lipid and glucose homeostasis [6, 7] . Disruption of the PPARa gene in mice revealed its role in fatty acid oxidation, fatty acid uptake and lipoprotein assembly and transport [8] . Fibrates improve lipid and lipoprotein metabolism by reducing chylomicron secretion by enterocytes and increasing TG catabolism through up-regulation of lipoprotein lipase (LPL) [9] and its activator apoAV [10] and by down-regulation of apoC-III [11e13] an inhibitor of LPL activity. Moreover, fibrates increase intestinal and hepatic HDL production [14] . Expression of the major HDL apolipoproteins, apoA-I and apoA-II [15, 16] , is induced by fibrates. PPARa activators control also cholesterol homeostasis in macrophages [17] . Macrophages are able to eliminate excess of cholesterol by specific efflux pathways by inducing cholesterol transporters like ABC transporter 1 (ABCA1) [18] or scavenger receptor BI (SR-B1) [19] towards apoA-I and HDL. By this way, cholesterol is carried by HDL particles to the liver where it is metabolised, a process called reverse cholesterol transport (RCT). Mice overexpressing apoA-I display increased macrophage RCT [20] , whereas mice deficient in apoA-I show reduced macrophage RCT [21] . In addition, PPARa also inhibits proinflammatory pathways by interfering with signaling pathways, such as nuclear factor (NF)-k B and activator protein (AP)-1 [22] in a DNA-binding independent manner [23] . The impact of PPARa on inflammation and atherosclerosis has been largely studied. In vitro and ex vivo studies suggest that PPARa activation may inhibit various inflammatory pathways by decreasing the production of pro-inflammatory cytokines induced by NF-kB, like the interleukins IL1 and IL6 [24] , as well as by repressing cytokine-induced expression of adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) [25] . Studies using PPARaÀdeficient mice crossed with models of atherosclerosis [26e28] and bone marrowderived macrophage transplant experiments demonstrated the anti-atherogenic effects of PPARa [29] .
Clinical studies, such as the Lopid Coronary Angiographic Trials (LOCAT), Bezafibrate Atherosclerosis Coronary Intervention Trial (BECAIT) and Diabetes Atherosclerosis Intervention Study (DAIS), have shown that fibrate therapy (gemfibrozil, bezafibrate or fenofibrate) reduces angiographically-assessed atherosclerosis progression. Moreover, outcome trials, such as the Veterans Affairshigh density lipoprotein cholesterol Intervention Trial (VA-HIT), Helsinki Heart Study (HHS), Bezafibrate Infarction Prevention study (BIP), Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) indicate that the beneficial effects of fibrates are most pronounced in patients with elevated triglycerides and low HDL-C [4, 30] . Nevertheless, some limitations of fibrate therapy are related to their weak activity on PPARa and their efficacy which depends on the targeted population. Novel compounds have been developed in the past decade, which are selective PPAR [31] modulators (SPPARMs) and have more potent PPARa agonist activity [32] . In this concept, the binding of PPAR ligands induces different conformational changes causing distinct patterns of cofactor recruitment and promoting selected biological responses [33] .
Given the potential of PPARa activation to control residual cardio vascular risk, we tested the effect of a new potent selective PPARa modulator pemafibrate (EC 50 on Gal4hPPARa ¼ 1 nM), which is currently in phase 3 clinical development [34] , on lipid and lipoprotein metabolism in apoE2KI mice, a model of atherogenic dyslipidemia, and in hapoA-I tg mice. In addition, the influence of pemafibrate on cholesterol efflux from macrophages towards HDL particles was studied in human primary macrophages. The effect of pemafibrate was further explored on RCT in hapoA-I tg mice. Finally, we examined the activity of pemafibrate on inflammation in macrophages, the vascular wall and on atherosclerosis in apoE2KI mice fed a western diet. . After a 60 min incubation at 20 C, cofactors expressed as a GST-fusion protein and adsorbed to a Sepharoseglutathione resin were added and agitated slowly on a rotating wheel for 90 min at 20 C. Unbound material was removed by three successive washes of the Sepharose beads in 1Â PBS-0.1% Triton X-100. Resin-bound receptors were then resolved by 8% SDS-PAGE and detected by autoradiography on PhosphorImager (Molecular Dynamics).
Materials and methods

GST pull down experiments
Cells and in vitro experiments
Caco-2/TC7 cells (from Pr Chambaz, Inserm 872, Paris, France) were routinely grown in complete medium (Dulbecco's modified essenial medium containing 25 mM glucose and glutamax; Gibco ® ). The medium was supplemented with 20% (v/v) of fetal calf serum, 1% (v/v) non-essential amino-acids and 1% (v/v) penicillin/ streptomycin. For experiments, cells were cultured for 4 weeks on microporous membrane inserts in assymmetric conditions before activation with the PPARa ligands (GW7647 at 600 nM, Fenofibric acid at 50 mM or pemafibrate at 0.1, 1 and 10 mM) added in the apical compartment in serum free complete medium. Basolateral media was collected after 24 h, followed by apoB quantification by the ELISA method (Mabtech ® , Nacha Strand, Sweden). THP1 and J774 cells were purchased from American Type Culture Collection ATCC and cultured in RPMI1640 medium containing gentamycin (40 mg/ml), 1% (v/v) glutamine and 10% (v/v) fetal calf serum. THP1 cells were differentiated into macrophages by exposure to phorbol-12myristate-13-acetate (PMA, Promega). THP1 macrophages were stimulated with LPS (100 ng/mL) in presence or not of PPARa ligands (Fenofibric acid or pemafibrate), and secreted cytokine levels were measured 24 h later with ELISA kits according to the manufacturer's instructions (R&D System). Cytokine mRNA levels were determined by quantitative PCR analysis.
J774 cells were grown in suspension in RPMI 1640 supplemented with 10% fetal calf serum and gentamycin (40 mg/mL). LDL was radiolabeled with 5 mCi/ml cholesterol efflux was measured.
Animal experiments
Female homozygous human apoE2KI mice, which express human apoE2 instead of mouse apoE [35] and display a human-like lipoprotein profile, were fed a western diet containing (wt/wt) 0.2% cholesterol and 21% fat (UAR, Epinay sur Orge, France) for 9 weeks and treated for the last 2 weeks with fenofibrate (250mpk) or pemafibrate (0.1 or 1mpk) or carboxy methyl cellulose (CMC, control) (n ¼ 10/group). Blood was collected after 4 h-fasting by sinus retroorbital puncture under isoflurane-induced anaesthesia for biochemical analysis. Mice were euthanized by cervical dislocation and liver, aortic arch and intestinal epithelium were removed and snap-frozen until further analysis.
For analysis of atherosclerotic lesions, male mice (n ¼ 9e10/ group) were fed a western diet supplemented or not (control group) with fenofibrate or pemafibrate for 10 weeks. Hearts were fixed with 4% phosphate-buffered paraformaldehyde (pH 7.0) and serial 10-mm-thick sections were cut between the valves and the aortic arch for quantitative analysis of lipid deposition by oil red-O staining. Images were captured with a JVC 3-charge-coupled device video camera. Sections were analyzed using the computer-assisted Quips Image analysis system (Leica Mikroskopic und System GmbH, Wetzlar, Germany).
Female human apoA-I tg mice (n ¼ 6/group) were treated with fenofibrate at 250mpk or pemafibrate at 0.1 or 1mpk for 2 weeks. Blood was collected after 4 h-fasting for biochemical analysis. In another experiment, mice were treated with fenofibrate at 250mpk or pemafibrate at 1mpk or CMC (control) during 2 weeks before intraperitoneal injection of radiolabeled [ 3 H]-cholesterol radiolabeled macrophages. Feces were collected during 48 h and were stored at À20 C before fecal cholesterol extraction.
Lipid and lipoprotein analysis
Plasma levels of total cholesterol (TC) and triglycerides (TG) were measured using commercially available kits (BoehringerMannheim, Germany; BioM erieux, France respectively). High density lipoprotein-cholesterol (HDL-C) concentrations were determined after precipitation of apoB-containing lipoproteins with phosphotungstic acid/Mg (Boehringer-Mannheim, Germany). Non-HDL cholesterol (N-HDL-C) values were calculated by substracting HDL-cholesterol from total cholesterol.
Lipoprotein cholesterol distribution profiles were obtained by gel filtration chromatography using a Superose 6 HR 10/30 column (Amersham Pharmacia Biotech) on pooled plasma samples from each group.
Fecal cholesterol extraction
Feces collected from 0 to 48 h were weighed and fecal cholesterol were extracted. Results are expressed as counts per min in total feces by wet weight.
RNA extraction and analysis
Total RNA was extracted from livers and aortic crosses by using the acid guanidinium isothiocyanate/phenol/chloroform method or from cells or scrapped intestinal epithelium using Extract All reagent. For quantitative PCR, RNA was reverse transcribed using random hexamer primers and Moloney murine leukemia virusreverse transcriptase (Applied Biosystems ® ). RNA levels were determined by real time quantitative polymerase chain reaction on MX-3000 apparatus (Agilent ® ) and specific primers (Eurogentec ® ) (Suppl. Table I ). Gene expression levels were expressed as mean ± SD relative to cyclophilin.
Statistical analysis
Statistical significance was determined by using a Student's ttest for real-time quantitative PCR and ELISA assays and by using and ANOVA followed by the post hoc Sheffe test for animal experiments. P values < 0.05 were considered as significant and different levels of significance are represented by asterisks: *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Pemafibrate improves lipoprotein metabolism
To investigate the effects of pemafibrate on plasma lipids, homozygous human apoE2KI displaying mixed dyslipidemia, were fed a western diet during 7 weeks and subsequently treated with or without fenofibrate (250mpk, the highest tolerable preclinical dose) or pemafibrate for 2 weeks. Compared to control mice, pemafibrate at 0.1 and 1mpk strongly reduced plasma TC (À72% and À79% respectively, p < 0.001) and TG (À68% and À85%, p < 0.001) concentrations with a decrease of N-HDL-C levels (À76% and À87%, p < 0.001) (Fig. 1) . The reference compound fenofibrate, given at a maximal efficacious dose of 250mpk, also lowered plasma lipids but to a lesser extend (TC, À58%, p < 0.001; TG, À18%, p < 0.05 and N-HDL-C, À61%, p < 0.001). ApoB mRNA levels, coding for an apolipoprotein essential for the assembly of chylomicrons and very low density lipoproteins (VLDL) in the intestine and the liver respectively, decreased gradually upon treatment with pemafibrate at 1mpk along the intestinal track [duodenum À75% (p < 0.001), jejunum À60% (p < 0.001), ileum À41% (p < 0.01)], while fenofibrate reduced apoB mRNA by only 42% in the duodenum (p < 0.01) (Fig. 2) . Hepatic apoB mRNA levels did not change upon treatment with either fenofibrate or K877 (data not shown).
To test for a direct effect on apoB secretion by intestinal epithelial cells, polarized Caco-2/TC7 cells grown and polarized on a porous filter to mimic the human intestinal barrier, were treated with the different PPARa ligands added to the apical side. After 24 h, medium in the basolateral compartment was collected, chylomicrons isolated by centrifugation and apoB quantified by ELISA.
Fenofibric acid (50 mM) slightly reduced (À18%) apoB secretion in the medium. GW7647, another synthetic PPARa agonist (600 nM) and pemafibrate (10 mM) significantly decreased apoB secretion [À30% (p < 0.05) and À73% (p < 0.01), respectively] (Fig. 2C) .
Moreover, hepatic mRNA levels of apoC-III, an inhibitor of LPL activity controlling TG clearance, decreased by 38% (p < 0.001) and 61% (p < 0.001) with pemafibrate at 0.1mpk and 1mpk respectively. Fenofibrate decreased apoC-III mRNA by 36% (p < 0.01) (Fig. 2B) . HDL-C levels strongly increased upon pemafibrate at 0.1mpk and 1mpk (þ104%, p < 0.01 and þ 252%, p < 0.001), while fenofibrate only induced a 75% (p < 0.01) increase of HDL-C in apoE2KI mice (Fig. 1) . In human apoA-I tg mice, a mouse model in which plasma cholesterol is mainly carried by HDL particles, pemafibrate and apo B mRNA level apo B mRNA level Fig. 2 . Effects of pemafibrate, GW647 and fenofibric acid on mRNA levels of genes involved in triglyceride metabolism in the liver and intestine of apoE2KI mice and on apoB secretion by polarized Caco-2/TC7 cells. mRNA levels of intestinal apoB (A) and hepatic apoC-III (B) were determined by quantitative PCR analysis. White bar, control (C) group; black bar, fenofibrate (F) (250mpk) treated mice; hatched bar, pemafibrate at 0.1mpk; grey bar, pemafibrate at 1mpk. Data are presented relative to control. Chylomicrons were isolated by ultracentrifugation followed by apoB quantification (ELISA) in polarized Caco-2/TC7 treated cells (C). White bar, control (C) cells; hatched bar, GW7647 (GW) (600 nM); black bar, fenofibric acid (FA) (50 mM) treated cells; hatched bar, pemafibrate at the indicated doses. *p < 0.05, **p < 0.01, ***p < 0.001. fenofibrate significantly induced TC (þ409%, p < 0.001; 248%, p < 0.001, respectively) (Fig. 3A) . Separation of the different lipoproteins by gel filtration confirmed the robust increase of cholesterol in HDL particles, with a stronger effect observed with pemafibrate at 1mpk compared to fenofibrate at 250mpk (Fig. 3B) . Increased HDL-C was associated with a concomitant increase in plasma human apoA-I upon pemafibrate and fenofibrate treatment (þ194%, p < 0.001; þ146%, p < 0.001, respectively) (Fig. 3A) .
Pemafibrate promotes cholesterol efflux in vitro and reverse cholesterol transport (RCT) in human apoA-I tg mice
To determine the activity of pemafibrate on cholesterol trafficking, human primary macrophages were treated with the PPARa ligands and the expression of the cholesterol transporters adenosine triphosphate (ATP)-binding cassette transporters ABCA1 and ABCG1 quantified. Cholesterol efflux to HDL particles was also assessed in labelled cholesterol-loaded macrophages. Pemafibrate strongly induced ABCA1 (þ563%, p < 0.01 at 10 mM) and ABCG1 (þ2093% p < 0.001 at 10 mM) mRNA steady-state levels in a dosedependent manner, being again more active than fenofibrate (þ168%, p < 0.05 for ABCA1 and þ506%, p < 0.01 for ABCG1) (Fig. 4A) . Moreover, pemafibrate more pronouncedly induced cholesterol efflux to HDL compared to fenofibrate (1.9-fold, p < 0.05 vs 1.6-fold, p < 0.05 respectively) (Fig. 4B) 
Pemafibrate has anti-inflammatory activities in macrophages in vitro and in the aorta in vivo
To determine the anti-inflammatory activity of pemafibrate, mRNA and protein expression of diverse chemo-and cytokines, like monocyte chemoattractant protein 1 (MCP1), interleukin 6 (IL6) and tumor necrosis factor alpha (TNFa), were measured in human THP-1 macrophages treated with the different PPARa ligands prior to LPS-activation. Pemafibrate dose-dependently repressed MCP1 (À90%, p < 0.001) and IL6 (À95%, p < 0.01) mRNA levels, while fenofibrate (at 100 mM) showed intermediate efficiency (À56%, p < 0.001 for MCP1 and À60%, p < 0.01 for IL6) (Suppl. Fig. IA) . Similarly, secretion of MCP1 and IL6 also decreased upon incubation with pemafibrate and fenofibrate (around À90%, p < 0.001 for pemafibrate as compared to À50%, p < 0.05 for fenofibric acid) (Suppl. Fig. IB) . In addition, TNFa secretion, but not mRNA, was reduced by pemafibrate (À85%, p < 0.001) (Suppl. Fig. I ). To determine the anti-inflammatory effect in vivo, vascular inflammation was determined in apoE2KI mice fed a western diet supplemented or not with pemafibrate or fenofibrate during 10 weeks. Expression of VCAM-1, the macrophage marker F4/80, MCP1 and IL6 decreased in pemafibrate treated mice (at 1mpk, À32%, p < 0.01 for VCAM-1, À30%, p < 0.01 for F4/80, À21%, ns for MCP1 and e40%, p < 0.05 for IL6), while fenofibrate had only a minor effect (NS) on these parameters (Fig. 5A) . As in previous experiments, a higher efficacy of pemafibrate was observed as compared to fenofbrate. 
Pemafibrate decreases atherosclerotic lesions in western dietfed apoE2KI mice
To assess whether pemafibrate treatment influences atherosclerosis, atherosclerotic lesion areas were measured by Oil-Red-O lipid staining in apoE2KI mice fed a western diet and treated during 10 weeks with pemafibrate at 0.1mpk and 1mpk. Both doses of pemafibrate significantly reduced atherosclerotic lesion areas by 71 and 89% respectively as compared to control mice (median: 0.061 mm 2 at 0.1mpk and 0.022 mm 2 at 1mpk versus 0.207 mm 2 in control mice; p < 0.001) indicating a dose-response effect of pemafibrate treatment (Fig. 5B and C) . Fenofibrate reduced atherosclerotic lesion sizes to a slightly lower extend than pemafibrate (median: 0.06 mm 2 in fenofibrate treated mice vs 0.207 mm 2 in control mice; p < 0.001) (Fig. 5B and C) .
Pemafibrate induces a distinct co-factor recruitment profile compared to fenofibrate
To determine whether the different activities of pemafibrate and fenofibrate may be related to ligand-specific conformational changes of PPARa resulting in formation of coactivator complexes, GST pull-down experiments were carried out (Suppl. Fig. II) . Pemafibrate more efficiently promoted the recruitment of coactivators SRC-1, PGC1a and GRIP1 than fenofibric acid, whereas DRIP205 was recruited to a similar extent.
Discussion
PPARa activators such as fibrates are useful drugs in the treatment of dyslipidemia characterized by elevated triglycerides and reduced HDL-C levels [30] . The effect of PPARa agonists on TG lowering is mainly attributed to the regulation of genes involved in lipid absorption, trafficking and metabolism. The intestine and the liver are major organs participating in the synthesis of apolipoproteins and the production of lipoproteins. ApoB is present exclusively in atherogenic lipoproteins such as chylomicrons, VLDL, IDL and LDL which carry cholesterol to peripheral tissues. PPARa activation not only decreases the secretion of apoB by enterocytes [14] , but also promotes TG catabolism by enhancing fatty acid oxidation and inducing LPL gene transcription in liver and muscle [9] . In addition, PPARa agonists down-regulate the expression of the LPL inhibitor apoC-III [11, 13] , and induce the LPL activator apoA-V [10] . ApoA-I is the major apolipoprotein of HDL particles, which promote cholesterol efflux from peripheral tissues to the liver, from where it is excreted into the bile and eliminated into feces, a process called RCT. PPARa agonists induce hepatic apoA-I synthesis and HDL production [8, 15, 16] . Moreover PPARa activation controls cholesterol trafficking in human macrophages [17] and induces the expression of cholesterol transporters ABCA1, ABCG1 in macrophages. As a result, PPARa activation enhances the first step of RCT. Altogether these activities are thought to be atheroprotective. In this study, we characterized the pharmacodynamic activity of a novel potent and SPPARMa pemafibrate, currently in phase 3 clinical trials [34] , on lipid metabolism by using humanized mouse models of mixed dyslipidemia (apoE2KI mice) and elevated HDL (human apoA-I tg mice) and compared its activity to fenofibrate, the clinically used reference compound, tested at its highest preclinical dose. In apoE2KI mice, pemafibrate markedly decreases TG and N-HDLC. Moreover, pemafibrate decreases apoB expression in the intestine through a direct action on enterocytes as shown using polarized Caco2/TC7 cells. Moreover, pemafibrate decreases apoC-III gene expression in the liver, which suggests an increased lipolytic activity which can contribute to the TG-lowering effect of this compound. In Sprague-Dawley rats, it has been demonstrated that daily treatment with pemafibrate at a dose of 1mpk or fenofibrate at 100mpk equivalently reduce TG concentrations by about 50% [35] . This TG-lowering effect is associated with a decrease of two LPL-regulating factors, apoC-III and angiopoietin-like 3 (ANGPTL3) resulting in a 2-fold increased plasma LPL activity [35] . Beside accelerating TG clearance, pemafibrate also reduced in rats de novo TG synthesis by 72% as well as the expression of the lipogenic genes FAS, ACC and DGAT2. Furthermore, fatty-acid b-oxidation increased upon pemafibrate treatment [35] . Altogether these observations provide an explanation for the TG-lowering activity of pemafibrate.
HDL-C concentrations increased in apoE2KI and human apoA-I tg mice upon pemafibrate treatment. The increase of HDL-C was associated with an increase of human apoA-I concentrations. Our data on TG and HDL-C are in line with results from phase II/III clinical studies showing that pemafibrate significantly improves plasma lipoprotein profiles in Japanese patients with dyslipidemia [36] . Among the HDL particles, small HDL (HDL 3 ) have been reported to be more efficient than large HDL (HDL 2 ) in RCT [37, 38] and the shift in lipoprotein subclass distribution could contribute to reduce the risk of atherosclerosis and coronary heart disease in man. Pemafibrate treatment (12 weeks) of Japanese patients caused a shift in HDL composition towards smaller particles increasing HDL 3 -C levels [39] . ApoA-I and HDL promote excess cholesterol efflux from peripheral tissues and transport towards the liver after which cholesterol is excreted into the bile and feces [20] . Clinical [38, 40] and transgenic mouse model [21] studies have established that HDL function are inversely correlated with cardiovascular disease. Moreover, recent studies showed that efflux capacity of HDL, rather than its cholesterol content, determines its atheroprotective activity [41] . In human primary macrophages, pemafibrate and fenofibrate promote cholesterol efflux towards HDL particles by increasing expression of the ABCA1 and ABCG1 cholesterol transporters. To examine the functionality of apoA-I and HDL induction by pemafibrate and fenofibrate on RCT, cholesterol, likely through induction of apoA-I and HDL particles as shown by Rader et al. [20] , just like in hapoA-I tg mice treated with fenofibrate [42] . Numerous studies in PPARa-deficient mice have implicated PPARa in the control of the inflammatory response. In PPARaKO mice, levels of inflammatory makers, such as VCAM1, are increased in murine endothelial cells [43] , aortas display an exacerbated inflammatory response to LPS stimulation [22] . Furthermore, the response to inflammatory stimuli in macrophages is enhanced [29] . Pemafibrate treatment repressed LPS induction of inflammatory cytokines like MCP1, IL6 and TNFa in macrophages. In apoE2KI mice fed a western diet to promote atherosclerosis development, inflammatory and macrophage makers are also decreased by pemafibrate in the aortas. In these mice, pemafibrate and fenofibrate also reduce the atherosclerotic lipid burden. It is important to note that in all experiments lower doses of pemafibrate than of fenofibrate were used, and that, nevertheless, pemafibrate showed a higher efficacy than fenofibrate. Co-factor recruitment assays showed more efficient association of co-activators SRC-1, PGC1a and GRIP1, in the presence of pemafibrate compare to fenofibric acid, while recruitment of DRIP 205 with pemafibrate was similar to those with fenofibric acid indicating that it functions as a SPPARM which may contribute to the differential biological activities of pemafibrate measured in vitro and in vivo. Therefore, we conclude that the highly potent selective PPARa modulator pemafibrate exerts protective anti-atherogenic properties in mice by its TG and remnant lipoprotein-lowering effect, its beneficial effect on HDL metabolism and RCT, and its anti-inflammatory activity in macrophages and the arterial wall resulting in reduced atherosclerosis burden. Thus, pemafibrate is an interesting novel SPPARMa to treat atherogenic dyslipidemia and cardiovascular disease risk.
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